MUC 15 Promotes Osteosarcoma Cell Proliferation, Migration and Invasion through Livin, MMP-2/MMP-9 and Wnt/β-Catenin Signal Pathway

被引：14

作者：

Chen, Tonglei ^{[1
]}

Chen, Zhenshi ^{[2
,3
]}

Lian, Xiaoning ^{[4
]}

Wu, Weidong ^{[2
,3
]}

Chu, Lei ^{[2
,3
]}

Zhang, Shaoru ^{[2
,3
]}

Wang, Lihui ^{[2
,3
]}

机构：

[1] Suzhou Ninth Peoples Hosp, Suzhou 215200, Jiangsu, Peoples R China

[2] Danyang Peoples Hosp Jiangsu Prov, Danyang 212300, Jiangsu, Peoples R China

[3] Nantong Univ, Danyang Hosp, Danyang 212300, Jiangsu, Peoples R China

[4] TOT BIOPHARM Co LTD, Dept Assay Dev, Suzhou 215024, Jiangsu, Peoples R China

来源：

JOURNAL OF CANCER | 2021年 / 12卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Osteosarcoma; MUC; 15; proliferation; migration; invasion; EXPRESSION; PROGNOSIS; METASTASIS; SURVIVAL; THERAPY;

D O I：

10.7150/jca.49641

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objective: To investigate the high expression of MUC15 in promoting proliferation, migration and invasion in osteosarcoma (OS) cell and its potential mechanism. Methods: The expressions of MUC15 in OS patients were analyzed from GEO Datasets, tumor cell lines and clinical samples. The roles of MUC15 in OS were explored by CCK-8, flow cytometry, transwell and western blot assay, respectively. Results: MUC15 was highly expressed in osteosarcoma, and there was a significant negative correlation between MUC15 and the prognosis. Knockdown of MUC15 in HOS and U-2OS could promote tumor cell apoptosis, down-regulate the expression of MMP2/9, reduce the epithelial interstitial transition and silence the Wnt/b-Catenin signal pathway. Conclusion: The high-expression of MUC15 promotes the proliferation, migration and invasion of osteosarcoma through anti-apoptosis, increasing the invasive ability by epithelial interstitial transition, and activating the Wnt/beta-Catenin signal pathway.

引用

页码：467 / 473

页数：7

共 30 条

[1] Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies [J].

Abarrategi, Ander ;

Tornin, Juan ;

Martinez-Cruzado, Lucia ;

Hamilton, Ashley ;

Martinez-Campos, Enrique ;

Rodrigo, Juan P. ;

Victoria Gonzalez, M. ;

Baldini, Nicola ;

Garcia-Castro, Javier ;

Rodriguez, Rene .

STEM CELLS INTERNATIONAL, 2016, 2016

[2] Update on Survival in Osteosarcoma [J].

Anderson, Megan E. .

ORTHOPEDIC CLINICS OF NORTH AMERICA, 2016, 47 (01) :283-+

[3] Immune Therapy for Sarcomas [J].

Anderson, Peter M. .

IMMUNOTHERAPY, 2017, 995 :127-140

[4]

Bielack Stefan S, 2016, F1000Res, V5, P2767

[5] Future directions in the treatment of osteosarcoma [J].

Bishop, Michael W. ;

Janeway, Katherine A. ;

Gorlick, Richard .

CURRENT OPINION IN PEDIATRICS, 2016, 28 (01) :26-33

[6]

Del Mare S, 2011, AM J CANCER RES, V1, P585

[7] Solitary Skeletal Osteosarcoma Recurrence. Findings From the Cooperative Osteosarcoma Study Group [J].

Franke, Markus ;

Hardes, Jendrik ;

Helmke, Knut ;

Jundt, Gernot ;

Juergens, Heribert ;

Kempf-Bielack, Beate ;

Kevric, Matthias ;

Tunn, Per-Ulf ;

Werner, Mathias ;

Bielack, Stefan .

PEDIATRIC BLOOD & CANCER, 2011, 56 (05) :771-776

[8] Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R) [J].

Geller, David S. ;

Morris, Jonathan ;

Revskaya, Ekaterina ;

Kahn, Mani ;

Zhang, Wendong ;

Piperdi, Sajida ;

Park, Amy ;

Koirala, Pratistha ;

Guzik, Hillary ;

Hall, Charles ;

Hoang, Bang ;

Yang, Rui ;

Roth, Michael ;

Gill, Jonathan ;

Gorlick, Richard ;

Dadachova, Ekaterina .

NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) :812-817

[9] Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy [J].

Gianferante, D. Matthew ;

Mirabello, Lisa ;

Savage, Sharon A. .

NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (08) :480-491

[10] Current and future therapeutic approaches for osteosarcoma [J].

Harrison, Douglas J. ;

Geller, David S. ;

Gill, Jonathan D. ;

Lewis, Valerae O. ;

Gorlick, Richard .

EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (01) :39-50

← 1 2 3 →